Therapeutics News and Research

RSS

Bundibugyo virus outbreak triggers international public health emergency declaration

Pursuant to paragraph 2 of Article 12 - Determination of a public health emergency of international concern, including a pandemic emergency of the International Health Regulations (2005) (IHR), the Director-General of the World Health Organization (WHO), after having consulted the States Parties where the event is known to be currently occurring, is hereby determining that the Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of pandemic emergency, as defined in the IHR.

18 May 2026

Gut microbiome metabolite butyrate relieves chronic jaw joint pain

Temporomandibular joint (TMJ) pain is associated with disrupted gut microbiome metabolites. Researchers reveal that butyrate, administered as tributyrin, alleviates pain by restoring histone acetylation and reversing gene regulatory changes in the brain.

18 May 2026

Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit

As the pace of modern drug discovery accelerates, the industry is increasingly recognizing that a breakthrough molecule is only as effective as its ability to reach the target site.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

Scientists call for innovative strategies to combat tuberculosis superspreaders

Superspreading became a familiar concept to many during the COVID-19 pandemic. Prior studies examining infectious disease epidemics, including those on COVID-19, have found that some individuals are much more likely to transmit infections to other people. Superspreading, when one person with an infection passes it to an unusually large number of other people, is a key feature of tuberculosis (TB) epidemiology.

15 May 2026

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

Stanford scientists map the molecular diversity of different global populations

Researchers at the Stanford School of Medicine have found that ethnicity and geography may influence human molecular makeup - from metabolism and immunity to gut microbiota and biological aging.

14 May 2026

Solving the mystery of ALS survival differences with new biological insights

Patients with ALS, or Lou Gehrig's disease, live an average of only three years after symptoms begin, though some can survive closer to 10 years. What drives these differences in survival has remained a mystery.

14 May 2026

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026

Base editing approach repairs deadly Dravet syndrome mutation in mice

Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of childhood epilepsy. After the edit, the mice have far fewer seizures and live much longer.

13 May 2026

Too little or excessive sleep may accelerate organ aging

An analysis of biological clocks throughout the human body suggests that too few hours of sleep-and too many-may speed aging in the brain, heart, lung, and immune system and is associated with a wide range of diseases.

13 May 2026

Scientists identify genetic mechanisms connected to core autism behaviors

A long‑overlooked stretch of the human genome appears to play a distinct role in shaping the social and stereotypic repetitive behaviors that define Autism Spectrum Disorder (ASD), without affecting learning or other cognitive abilities, according to a major new study published in Nature.

13 May 2026

New drug carrier improves cancer treatment by anchoring to tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, which means they need to stay near the diseased tissues long enough.

13 May 2026

Study explains how APOE2 gene protects the brain against Alzheimer's disease

People who carry the APOE2 version of the apolipoprotein E gene are more likely to live to advanced age and are partly protected against Alzheimer's disease, but scientists have struggled to explain why.

13 May 2026

Penn researchers develop ApexGO to enhance promising antibiotic candidates

Researchers at the University of Pennsylvania have developed ApexGO, a novel, AI-powered method for turning promising but imperfect antibiotic candidates into more potent ones.

13 May 2026

Dual-pathway protein degradation approach could improve cancer treatment

Targeted protein degradation has become one of the most promising strategies in modern drug discovery, enabling scientists to eliminate disease-causing proteins instead of merely blocking them.

12 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

Using AI to improve success rates of fecal microbiota transplants

MOZAIC leverages deep learning to optimize fecal microbiota transplantation, enhancing treatment efficacy through precise donor-recipient microbiome matching.

12 May 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Cardiometabolic diseases remain leading cause of excess American mortality

Between 1999 and 2022, the US had substantially higher death rates than other wealthy nations, largely due to cardiovascular disease, metabolic diseases (including diabetes), Alzheimer's disease and related dementias, and drug and alcohol complications.

8 May 2026